ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Clinical Trials Approved By NCI Last Month Are Listed

August 29, 2003

Raising NIH Appropriations Is High Priority, House Subcommittee Chairman Says

March 7, 1997

IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies

May 8, 1987

New DRCCA Board Skeptical Of CIs renewal, Proposal For Cytopathology

September 26, 1980

FDA Selects 23 Survivors To Review Drug Applications.

June 15, 2001

FDA Approves Velcade Injection In Mantle Cell Lymphoma

October 31, 2014